ARS Pharmaceuticals (SPRY) Retained Earnings (2020 - 2026)

ARS Pharmaceuticals has reported Retained Earnings for 6 years, with the latest figure at -$355.2 million in Q1 2026.

• Quarterly Retained Earnings fell 191.99% year-over-year to -$355.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$355.2 million (down 191.99% YoY) and the FY2025 annual result came in at $125000.0, down 99.97% from the prior year.
• Retained Earnings slipped to -$355.2 million in Q1 2026 per SPRY's latest filing, from $125000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $510.6 million in Q2 2022 and troughed at -$355.2 million in Q1 2026.
• A 5-year average of $150.0 million and a median of $407000.0 in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 537513.24% in 2024, then plunged 191.99% in 2026.
• Over 5 years, Retained Earnings stood at $407000.0 in 2022, then soared by 88844.47% to $362.0 million in 2023, then advanced by 4.94% to $379.9 million in 2024, then tumbled by 99.97% to $125000.0 in 2025, then sank by 284276.8% to -$355.2 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$355.2 million, $125000.0, and -$7000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.